Handelsbanken Fonder AB Grows Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Handelsbanken Fonder AB lifted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,900 shares of the medical technology company’s stock after buying an additional 1,000 shares during the period. Handelsbanken Fonder AB’s holdings in Alphatec were worth $316,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ATEC. BluePath Capital Management LLC acquired a new stake in shares of Alphatec during the third quarter worth about $29,000. RiverPark Advisors LLC acquired a new position in Alphatec during the third quarter worth approximately $53,000. Provence Wealth Management Group purchased a new stake in Alphatec in the third quarter valued at approximately $56,000. Van ECK Associates Corp acquired a new stake in shares of Alphatec in the third quarter valued at approximately $113,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Alphatec by 23.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,120 shares of the medical technology company’s stock valued at $157,000 after acquiring an additional 2,331 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alphatec

In related news, CFO John Todd Koning sold 37,500 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the sale, the chief financial officer now owns 393,356 shares of the company’s stock, valued at $5,042,823.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO John Todd Koning sold 37,500 shares of Alphatec stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the transaction, the chief financial officer now directly owns 393,356 shares of the company’s stock, valued at $5,042,823.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 41,560 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $15.05, for a total value of $625,478.00. Following the completion of the sale, the executive vice president now directly owns 1,188,444 shares in the company, valued at approximately $17,886,082.20. The disclosure for this sale can be found here. Insiders have sold a total of 285,069 shares of company stock valued at $3,971,495 in the last ninety days. 29.12% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. Needham & Company LLC raised their price target on Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Wells Fargo & Company started coverage on Alphatec in a research report on Friday, February 9th. They issued an “overweight” rating and a $26.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.63.

Alphatec Stock Performance

NASDAQ ATEC opened at $13.21 on Friday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -8.52 and a beta of 1.48. The business’s 50 day moving average is $13.42 and its two-hundred day moving average is $13.51. Alphatec Holdings, Inc. has a 12-month low of $8.66 and a 12-month high of $19.14. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $131.90 million. Alphatec’s quarterly revenue was up 30.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) EPS. Research analysts expect that Alphatec Holdings, Inc. will post -1.1 EPS for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.